Formula IV Solubilizing Agent Composition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Poorly water-soluble drugs face challenges with low bioavailability, stability issues, and increased development costs due to their limited solubility and dissolution rates, particularly in cancer therapy applications.
Innovation Solution
A pharmaceutical composition comprising compounds of Formula IV, combined with a solubilizing agent, is developed to enhance solubility and stability, utilizing an amorphous form and specific excipients like polyvinylpyrrolidone and cyclodextrin, processed through methods like hot melt extrusion to achieve improved bioavailability and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If solubilizing agents are added to improve solubility, then bioavailability increases, but stability decreases
Solution Approach 1:
The patent uses amorphous carriers as intermediary substances to solubilize poorly water-soluble drugs without compromising stability. The amorphous form acts as a mediator that enhances dissolution and bioavailability while maintaining physical and chemical stability during storage, resolving the contradiction between improved bioavailability and maintained stability.
2Stability of the object's composition
If crystalline form is used for stability, then storage stability improves, but dissolution rate decreases
Solution Approach 1:
The patent employs phase transition by converting the drug from crystalline form to amorphous form. This phase change enables the drug to achieve both improved dissolution rate and storage stability, as the amorphous form provides enhanced solubility and dissolution while maintaining stability through proper formulation and storage conditions.
3Speed
If particle size is reduced to improve dissolution, then dissolution rate increases, but manufacturing complexity increases
Solution Approach 1:
Instead of changing physical parameters like particle size, the patent changes the physical state parameter from crystalline to amorphous. This parameter change achieves enhanced dissolution rate without the manufacturing complexity associated with particle size reduction techniques, as the amorphous formulation can be produced using conventional processing methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition demonstrates significantly improved solubility and bioavailability, maintaining stability up to 18 months in packed form, and exhibits enhanced drug release profiles, addressing the challenges of poor solubility and stability in existing drug formulations.
Implementation Method 1
Solubilizing agents, such as surfactants, are solubilizer excipients added to pharmaceutical formulations in order to increase the solubility of poorly soluble drugs
Implementation Method 2
The compound or a pharmaceutically acceptable salt of Formula IV, in the said pharmaceutical composition is amorphous
Data Source
AI summary
The present invention relates to pharmaceutical compositions comprising compound of Formula IV, along with a solubilizing agent and a process to prepare the same. The said pharmaceutical compositions have enormous applications in cancer therapy. The present invention has come up with a novel and innovative pharmaceutical composition for the compounds of Formula IV that show significant stability as well as the desired bioavailability on drug release.